{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:53Z","timestamp":1792788353696,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00198-015-3145-7","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T09:25:32Z","timestamp":1432027532000},"page":"21-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study"],"prefix":"10.1007","volume":"27","author":[{"given":"K. E.","family":"Naylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paggiosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gossiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. F. A.","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"3145_CR1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","volume":"1068","author":"RG Russell","year":"2006","unstructured":"Russell RG (2006) Bisphosphonates: from bench to bedside. Ann NY Acad Sci 1068:367\u2013401","journal-title":"Ann NY Acad Sci"},{"key":"3145_CR2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF03324588","volume":"17","author":"JD Adachi","year":"2005","unstructured":"Adachi JD, Rizzoli R, Boonen S, Li Z, Meredith MP, Chesnut CH 3rd (2005) Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin Exp Res 17:150\u2013156","journal-title":"Aging Clin Exp Res"},{"key":"3145_CR3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"3145_CR4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"3145_CR5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"3145_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"3145_CR7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"3145_CR8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"IC Chesnut","year":"2004","unstructured":"Chesnut IC, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"3145_CR9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391\u2013420","journal-title":"Osteoporos Int"},{"key":"3145_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","volume":"20","author":"BL Riggs","year":"2005","unstructured":"Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177\u2013184","journal-title":"J Bone Miner Res"},{"key":"3145_CR11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","volume":"20","author":"M Arlot","year":"2005","unstructured":"Arlot M, Meunier PJ, Boivin G et al (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244\u20131253","journal-title":"J Bone Miner Res"},{"key":"3145_CR12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141\u2013151","journal-title":"J Bone Miner Res"},{"key":"3145_CR13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clinthera.2009.04.018","volume":"31","author":"R Emkey","year":"2009","unstructured":"Emkey R, Delmas PD, Bolognese M et al (2009) Efficacy and tolerability of once-monthly oral ibandronate (150\u00a0mg) and once-weekly oral alendronate (70\u00a0mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther 31:751\u2013761","journal-title":"Clin Ther"},{"key":"3145_CR14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","volume":"21","author":"DC Bauer","year":"2006","unstructured":"Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292\u2013299","journal-title":"J Bone Miner Res"},{"key":"3145_CR15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","volume":"13","author":"SL Greenspan","year":"1998","unstructured":"Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431\u20131438","journal-title":"J Bone Miner Res"},{"key":"3145_CR16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250\u20131258","journal-title":"J Bone Miner Res"},{"key":"3145_CR17","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.1644","volume":"27","author":"RM Jacques","year":"2012","unstructured":"Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5\u00a0mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:1627\u20131634","journal-title":"J Bone Miner Res"},{"key":"3145_CR18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrrheum.2012.86","volume":"8","author":"K Naylor","year":"2012","unstructured":"Naylor K, Eastell R (2012) Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 8:379\u2013389","journal-title":"Nat Rev Rheumatol"},{"key":"3145_CR19","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23:2769\u20132774","journal-title":"Osteoporos Int"},{"key":"3145_CR20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","volume":"13","author":"RA Hannon","year":"1998","unstructured":"Hannon RA, Blumsohn A, Naylor KE, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124\u20131133","journal-title":"J Bone Miner Res"},{"key":"3145_CR21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bone.2009.07.089","volume":"45","author":"A Rogers","year":"2009","unstructured":"Rogers A, Glover SJ, Eastell R (2009) A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 45:1044\u20131052","journal-title":"Bone"},{"key":"3145_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","volume":"22","author":"R Eastell","year":"2006","unstructured":"Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61\u201366","journal-title":"Curr Med Res Opin"},{"key":"3145_CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1742-1241.2008.01911.x","volume":"63","author":"P Bergmann","year":"2009","unstructured":"Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Reginster JY, Gangji V (2009) Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63:19\u201326","journal-title":"Int J Clin Pract"},{"key":"3145_CR24","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","volume":"25","author":"MA Paggiosi","year":"2014","unstructured":"Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R (2014) Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 25:2729\u20132741","journal-title":"Osteoporos Int"},{"key":"3145_CR25","unstructured":"CLSI (2008) Defining, establishing, and verifying reference intervals in the clinical laboratory; Clinical and Laboratory Standards Institute;, CLSI document C28-A3. Wayne, PA:"},{"key":"3145_CR26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s001980050247","volume":"10","author":"BM Ingle","year":"1999","unstructured":"Ingle BM, Hay SM, Bottjer HM, Eastell R (1999) Changes in bone mass and bone turnover following ankle fracture. Osteoporos Int 10:408\u2013415","journal-title":"Osteoporos Int"},{"issue":"Suppl 6","key":"3145_CR27","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","volume":"11","author":"R Hannon","year":"2000","unstructured":"Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30\u2013S44","journal-title":"Osteoporos Int"},{"key":"3145_CR28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA (2011) International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clin Chem Lab Med 49:1271\u20131274","journal-title":"Clin Chem Lab Med"},{"key":"3145_CR29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"3145_CR30","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00198-013-2386-6","volume":"24","author":"J Finigan","year":"2013","unstructured":"Finigan J, Naylor K, Paggiosi MA, Peel NF, Eastell R (2013) Adherence to raloxifene therapy: assessment methods and relationship with efficacy. Osteoporos Int 24:2879\u20132886","journal-title":"Osteoporos Int"},{"key":"3145_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","volume":"24","author":"PD Miller","year":"2008","unstructured":"Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 24:207\u2013213","journal-title":"Curr Med Res Opin"},{"key":"3145_CR32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"3145_CR33","first-page":"97","volume":"26","author":"MJ Seibel","year":"2005","unstructured":"Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97\u2013122","journal-title":"Clin Biochem Rev"},{"key":"3145_CR34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/PL00004183","volume":"11","author":"E Fink","year":"2000","unstructured":"Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC (2000) Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 11:295\u2013303","journal-title":"Osteoporos Int"},{"key":"3145_CR35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/10408360801949442","volume":"45","author":"SD Vasikaran","year":"2008","unstructured":"Vasikaran SD (2008) Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 45:221\u2013258","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3145_CR36","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB (2011) Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 26:1662\u20131669","journal-title":"J Bone Miner Res"},{"key":"3145_CR37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","volume":"137","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL, Emkey RD, Bone HG et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875\u2013883","journal-title":"Ann Intern Med"},{"key":"3145_CR38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00198-012-2097-4","volume":"24","author":"I Baxter","year":"2013","unstructured":"Baxter I, Rogers A, Eastell R, Peel N (2013) Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporos Int 24:941\u2013947","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3145-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3145-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3145-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:15:23Z","timestamp":1558610123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3145-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3145"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3145-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,20]]}}}